Symbol="ASLN"
AssetType="Common Stock"
Name="Aslan Pharmaceuticals Ltd ADR"
Description="ASLAN Pharmaceuticals Limited, a biopharmaceutical company focused on clinical phase immunology, is dedicated to developing various treatments to transform the lives of patients. The company is headquartered in Singapore."
CIK="1722926"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="83 CLEMENCEAU AVENUE, #12-03 UE SQUARE, SINGAPORE, SG"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="40704500"
EBITDA="-54072000"
PERatio="None"
PEGRatio="None"
BookValue="0.667"
DividendPerShare="0"
DividendYield="0"
EPS="-2.77"
RevenuePerShareTTM="0.005"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.447"
ReturnOnEquityTTM="-2.094"
RevenueTTM="189710"
GrossProfitTTM="79821000"
DilutedEPSTTM="-2.77"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="15.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="19.05"
PriceToBookRatio="1.584"
EVToRevenue="16.94"
EVToEBITDA="-0.062"
Beta="1.797"
num_52WeekHigh="4.945"
num_52WeekLow="1.702"
num_50DayMovingAverage="3.974"
num_200DayMovingAverage="3.213"
SharesOutstanding="16347200"
DividendDate="None"
ExDividendDate="None"
symbol="ASLN"
open="2.55"
high="2.59"
low="2.46"
price="2.54"
volume="235347.00"
latest_trading_day="2023-07-10"
previous_close="2.49"
change="0.05"
change_percent="2.0080%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="25"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="75"
Volume_recent_avg="130139"
Change_recent_avg="0.01"
Delta_recent_avg="0.25"
Variance_recent_avg="0.13"
Change_ratio_recent_avg="-0.29"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="75"
Aroon_momentum_negative="25"
image_negative_thumbnail_id_1="119"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0057.jpeg"
image_negative_thumbnail_id_2="1118"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0151.jpeg"
image_neutral_thumbnail_id_1="530"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_neutral_thumbnail_id_2="529"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0070.jpeg"
image_positive_thumbnail_id_1="1014"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0176.jpeg"
image_positive_thumbnail_id_2="993"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0155.jpeg"
image_professor_thumbnail_id_1="1167"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
